Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | MAP2K1 |
| Variant | F53_Q58delinsL |
| Impact List | indel |
| Protein Effect | gain of function - predicted |
| Gene Variant Descriptions | MAP2K1 F53_Q58delinsL results in a deletion of six amino acids of the Map2k1 protein from amino acids 53 to 58, combined with the insertion of a leucine (L) at the same site (UniProt.org). F53_Q58delinsL results in proliferation in low serum conditions similar to wild-type Map2k1 in a competition assay but results in increased transformation activity in cultured cells and increased proliferation in normal serum conditions in a competition assay (PMID: 36442478), and therefore, is predicted to lead to a gain of Map2k1 protein function. |
| Associated Drug Resistance | |
| Category Variants Paths |
MAP2K1 mutant MAP2K1 act mut MAP2K1 F53_Q58delinsL |
| Transcript | NM_002755.4 |
| gDNA | chr15:g.66435105_66435119del15 |
| cDNA | c.159_173del15 |
| Protein | p.F53_Q58delinsL |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| XM_017022411.2 | chr15:g.66435105_66435119del15 | c.159_173del15 | p.F53_Q58delinsL | RefSeq | GRCh38/hg38 |
| XM_017022411.3 | chr15:g.66435105_66435119del15 | c.159_173del15 | p.F53_Q58delinsL | RefSeq | GRCh38/hg38 |
| XM_017022411 | chr15:g.66435105_66435119del15 | c.159_173del15 | p.F53_Q58delinsL | RefSeq | GRCh38/hg38 |
| NM_002755.3 | chr15:g.66435105_66435119del15 | c.159_173del15 | p.F53_Q58delinsL | RefSeq | GRCh38/hg38 |
| NM_002755 | chr15:g.66435105_66435119del15 | c.159_173del15 | p.F53_Q58delinsL | RefSeq | GRCh38/hg38 |
| NM_002755.4 | chr15:g.66435105_66435119del15 | c.159_173del15 | p.F53_Q58delinsL | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| MAP2K1 F53_Q58delinsL | Advanced Solid Tumor | sensitive | Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, Mekinist (trametinib) inhibited viability of a transformed cell line expressing MAP2K1 F53_Q58delinsL in culture (PMID: 36442478). | 36442478 |